Lipoprotein apheresis: State of the art and novelties

Atherosclerosis Supplements

Volumn 14, Issue 1, 2013, Pages 19-27

  Stefanutti, C ^a   Julius, U ^b  

^a POLICLINICO UMBERTO I   (Italy)

^b UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

HDL enhancers; Lipoprotein apheresis; Lipoprotein apheresis in pregnancy; Lomitapide; Mipomersen; PCSK9 inhibitors; Pediatric treatment; Severe hypercholesterolemia

Indexed keywords

ATORVASTATIN; AVASIMIBE; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LAROPIPRANT; LAROPIPRANT PLUS NICOTINIC ACID; LOMITAPIDE; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MIPOMERSEN; NICOTINIC ACID; SIMVASTATIN;

APHERESIS; ARTICLE; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY BYPASS GRAFT; FAMILIAL HYPERCHOLESTEROLEMIA; HEART MUSCLE ISCHEMIA; HUMAN; HYPERLIPOPROTEINEMIA; HYPOTENSION; LIPOPROTEIN APHERESIS; NAUSEA; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRACTICE GUIDELINE; PRIORITY JOURNAL; UNSPECIFIED SIDE EFFECT;

AGE FACTORS; ANIMALS; BIOLOGICAL MARKERS; BLOOD COMPONENT REMOVAL; CARDIOVASCULAR DISEASES; HUMANS; HYPERLIPOPROTEINEMIAS; HYPOLIPIDEMIC AGENTS; LIPOPROTEINS; RISK FACTORS; TREATMENT OUTCOME;

EID: 84872848174     PISSN: 15675688     EISSN: 18785050     Source Type: Journal    
DOI: 10.1016/j.atherosclerosissup.2012.10.021     Document Type: Article

References (85)

1. Bosch T., Wendler T. State of art of LDL-apheresis in the year 2003. Ther Apher Dial 2004, 8:76-79.
2. Thompson G.R. Recommendations for the use of LDL apheresis. Atherosclerosis 2008, 198(2):247-255. HEART-UK LDL Apheresis Working Group.
3. Szczepiorkowski Z.M., Winters J.L., Bandarenko N., Kim H.C., Linenberger M.L., Marques M.B., et al. Guidelines on the use of therapeutic apheresis in clinical practice - evidence-based approach from the apheresis applications Committee of the American Society for Apheresis. J Clin Apher 2010, 25:83-177.
4. Stoffel W., Borberg H., Greve V. Application of specific extracorporeal removal of low density lipoprotein in familial hypercolesterolemia. The Lancet 1981, 318:1005-1007.
5. Saal Stuart D., Parker Thomas S., Gordon Bruce R., Studebaker Joel, Hudgins Lisa, Ahrens E.H., et al. Removal of low-density lipoproteins in patients by extracorporeal immunoadsorption. Am J Med 1986, 80:583-589.
6. Mabuchi Hiroshi, Michishita Ichiro, Takeda Mitsuaki, Fujita Hajime, Koizumi Junji, Takeda Ryoyu, et al. A new low density lipoprotein apheresis system using two dextran sulfate cellulose columns in an automated column regenerating unit (LDL continuous apheresis). Atherosclerosis 1987, 68:19-25.
7. Suzuki M., Yamane S., Matsugane T., Nobuto T., Azuma N., Nishide T., et al. Evaluation of double filtration plasmapheresis, thermofiltration, and low-density lipoprotein adsorptive methods by crossover test in the treatment of familial hypercholesterolemia patients. Artif Organs 1996, 20(4):296-302.
8. Stefanutti C., Di Giacomo S., Vivenzio A. Comparison between different techniques of LDL-apheresis. Int J Artif Organs 1997, 21(S-6):66-71.
9. Gordon B.R., Kelsey S.F., Dau P.C., et al. Long term effects of LDL-apheresis using automated dextran sulfate cellulose adsorption system. Am J Cardiol 1998, 81:407-411.
10. Julius U., Metzler W., Pietzsch J., Fassbender T., Klingel R. Intraindividual comparison of two extracorporeal LDL apheresis methods: lipidfiltration and HELP. Int J Artif Organs 2002, 25(12):1180-1188.
11. Stefanutti C., Di Giacomo S., Di Caro M., Vivenzio A., Musca A. DALI low-density lipoprotein apheresis in homozygous and heterozygous familial hypercholesterolemic patients using low-dose citrate anticoagulation. Ther Apher 2001, 5(5):364-371.
12. Bosch T., Lennertz A., Schenzle D., Drager J. Direct adsorption of low-density lipoprotein and lipoprotein(a) from whole blood: results of the first clinical long-term multicenter study using DALI apheresis. J Clin Apher 2002, 17(4):161-169.
13. Stefanutti C., Vivenzio A., Di Giacomo S., Mazzarella B., Notarbartolo A., Bertolini S., et al. LDL-apheresis in a homozygous familial hypercholesterolemic child aged 4.5. Artif Organs 1997, 21(10):1126-1137.
14. Stefanutti C., Di Giacomo S., Vivenzio A., Rabbone I., Cerutti F., Berni A., et al. LDL-apheresis in a patient aged 3.5. Acta Pediatr 2001, 90:1-7.
15. Tonstad S., Thompson G.R. Management of hyperlipidemia in the pediatric population. Curr Treat Options Cardiovasc Med 2004, 6(5):431-437.
16. Marais A.D., Naoumova R.P., Firth J.C., Penny C., Neuwirth C.K., Thompson G.R. Decreased production of low density lipoprotein by atorvastatin after apheresis in homozygous familial hypercholesterolemia. J Lipid Res 1997, 38(10):2071-2078.
17. Naoumova R.P., Marais A.D., Mountney J., Firth J.C., Rendell N.B., Taylor G.W., et al. Plasma mevalonicacid, an index of cholesterol synthesis in vivo, and responsiveness to HMG-CoA reductase inhibitors in familial hypercholesterolaemia. Atherosclerosis 1996, 119(2):203-213.
18. Naoumova R.P., Marais D., Firth J.C., Neuwirth C.Y., Taylor G.W., Thompson G.R. Atorvastatin augments therapy of homozygous familial hypercholesterolemia by inhibiting up-regulation of cholesterol synthesis after apheresis and bile acid sequestrant. Circulation 1996, 94:3410.
19. Thompson G.R., Miller J.P., Breslow J.L. Improved survival of patients with homozygous familial hypercholesterolaemia treated with plasma exchange. Br Med J (Clin Res Ed) 1985, 291(6510):1671-1673.
20. Mabuchi H., Koizumi J., Shimizu M., Kajinami K., Miyamoto S., Ueda K., et al. Long term efficacy of low density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Hokuriku FH LDL-apheresis Study Group. Am J Cardiol 1998, 82:1489-1495.
21. Leitinger N., Pirich C., Blazek I., Endler G., Sinzinger H. Decreased susceptibility of low-density lipoproteins to in-vitro oxidation after dextran-sulfate LDL-apheresis treatment. Atherosclerosis 1996, 126(2):305-312.
22. Stefanutti C., Di Giacomo S., Vivenzio A., Isacchi G.C., Masella R., Caprari P., et al. Acute and long-term effects of low-density lipoprotein (LDL)-apheresis on oxidative damage to LDL and reducing capacity of erythrocytes in patients with severe familial hypercholesterolaemia. Clin Sci (Lond) 2001, 100(2):191-198.
23. Tamai O., Matsuoka H., Itabe H., Wada Y., Kohno K., Imaizumi T. Single LDL apheresis improves endothelium-dependent vasodilatation in hypercholesterolemic humans. Circulation 1997, 95(1):76-82.
24. Knisel W., Di Nicuolo A., Pfohl M., Muller H., Risler T., Eggstein M., et al. Different effects of two methods of low density lipoprotein apheresis on the coagulation and fibrinolitic systems. J Intern Med 1993, 234:479-487.
25. Giansante C., Bordin P., Fiotti N., Calabrese S., Petrucco A., Da Col P.G., et al. Activation of coagulation by LDL-apheresis device. Blood Coagul Fibrinolysis 1996, 7:447-452.
26. Ritter M.M., Suhler K., Richter W., Schwandt P. Short- and long-term effects of LDL-apheresis on lipoprotein(a) serum levels. Clin Chim Acta 1990, 195(1-2):9-15.
27. Julius U., Siegert G., Gromeier S. Intraindividual comparison of the impact of two selective apheresis methods (DALI and HELP) on the coagulation system. Int J Artif Organs 2000, 3:199-206.
28. Wang Y., Blessing F., Walli A.K., Uberfuhr P., Fraunberger P., Seidel D. Effects of heparin-mediated extracorporeal low-density lipoprotein precipitation beyond lowering proatherogenic lipoproteins-reduction of circulating proinflammatory and procoagulatory markers. Atherosclerosis 2004, 175:145-150.
29. Hovland A., Hardersen R., Sexton J., Mollnes T.E., Lappegård K.T. Different inflammatory responses induced by three LDL-lowering apheresis columns. J Clin Apher 2009, 24(6):247-253.
30. Kojima S., Shida M., Yokoyama H. Changes in C-reactive protein plasma levels during low-density lipoprotein apheresis. Ther Apher Dial 2003, 7(4):431-434.
31. Stefanutti C., Morozzi C., Petta A. Lipid and low-density-lipoprotein apheresis. Effects on plasma inflammatory profile and on cytokine pattern in patients with severe dyslipidemia. Cytokine 2011, 56(3):842-849.
32. Agishi T., Kitano Y., Suzuki T., Miura A., Murakami J., Minagawa H., et al. Improvement of peripheral circulation by low density lipoprotein adsorption. ASAIO Trans 1989, 35(3):349-351.
33. Lechner P., Walzl M., Walzl B. The impact of H.E.L.P. on haemorheology in peripheral arterial disease. Clin Hemorheol 1994, 14:181-188.
34. Kitabatake A., Sato H., Hori M., Kamada T., Kubori S., Hoki N., et al. Coronary atherosclerosis reduced in patients with familial hypercholesterolemia after intensive cholesterol lowering with low-density lipoprotein-apheresis: 1-year follow-up study. The Osaka LDL-apheresis Multicenter Trial Group. Clin Ther 1994, 16(3):416-428.
35. Tatami R., Inoue N., Itoh H., Kishino B., Koga N., Nakashima Y., et al. Regression of coronary atherosclerosis by combined LDL-apheresis and lipid lowering therapy in patients with familial hypercholesterolemia: a multicenter study. The LAARS Investigators. Atherosclerosis 1992, 95:1-13.
36. Aengevaeren W.R., Kroon A.A., Stalenhoef A.F., Uijen G.J., van der Werf T. Low density lipoprotein apheresis improves regional myocardial perfusion in patients with hypercholesterolemia and extensive coronary artery disease. LDL-apheresis Atherosclerosis Regression Study (LAARS). J Am Coll Cardiol 1996, 28(7):1696-1704.
37. Nishimura S., Sekiguchi M., Kano T., Ishiwata S., Nagasaki F., Nishide T., et al. Effect of intensive lipid lowering by low density lipoprotein apheresis on regression of coronary atherosclerosis in patients with familial hypercholesterolemia: Japan Low Density Lipoprotein Apheresis Coronary Atherosclerosis Prospective Study (L-Caps). Atherosclerosis 1999, 144:409-417.
38. Fukuzawa S., Ozawa S., Inagaki M., Morooka S., Inoue T. Secondary prevention with lipid lowering therapy in familial hypercholesterolemia: a correlation between new evolution of stenotic lesion and achieved cholesterol levels after revascularization procedures. Intern Med 1999, 38(4):330-335.
39. Daida H., Lee Y.J., Yokoi H., Kanoh T., Ishiwata S., Kato K., et al. Prevention of restenosis after percutaneous transluminal coronary angioplasty by reducing lipoprotein(a) levels with low-density lipoprotein apheresis. Low-density Lipoprotein Apheresis Angioplasty Restenosis Trial (L-ART) Group. Am J Cardiol 1994, 73(15):1037-1040.
40. Klingel R., Fassbender C., Fassbender T., Göhlen B. Clinical studies to implement rheopheresis for age-related macular degeneration guided by evidence-based-medicine. Transfus Apher Sci 2003, 29(1):71-84.
41. Bianchin G., Russi G., Romano N., Fioravanti P. Treatment with HELP-apheresis in patients suffering from sudden sensorineural hearing loss: a prospective, randomized, controlled study. Laryngoscope 2010, 120(4):800-807.
42. Nohara A., Mabuchi H. Familial defective apolipoprotein B100: FDB. Nihon Rinsho 2001, 59(3):47-54.
43. Bochmann H., Geisel J., Herrmann W., Purcz T., Reuter W., Julius U., et al. Eight novel LDL receptor gene mutations among patients under LDL apheresis in Dresden and Leipzig. Hum Mutat 2001, 17(1):76-77.
44. Maher V.M., Kitano Y., Neuwirth C., Gallagher J.J., Thompson G.R., Myant N.B. Effective reduction of plasma LDL levels by LDL apheresis in familial defective apolipoprotein B-100. Atherosclerosis 1992, 95(2-3):231-234.
45. Soutar A.K., Naoumova R.P. Autosomal recessive hypercholesterolemia. Semin Vasc Med 2004, 4(3):241-248.
46. Sakuma N., Iwata S., Ikeuchi R., Ichikawa T., Hibino T., Kamiya Y., et al. Coexisting type III hyperlipoproteinemia and familial hypercholesterolemia: a case report. Metabolism 1995, 44(4):460-465.
47. Schettler V., Neumann C.L., Hulpke-Wette M., Hagenah G.C., Schulz E.G., Wieland E. Current view: indications for extracorporeal lipid apheresis treatment. Clin Res Cardiol Suppl 2012.
48. Baldassarre D., Tremoli E., Franceschini G., Michelagnoli S., Sirtori C.R. Plasma lipoprotein(a) is an independent factor associated with carotid wall thickening in severely but not moderately hypercholesterolemic patients. Stroke 1996, 27(6):1044-1049.
49. Nordestgaard B.G., Chapman M.J., Ray K., Boren J., Andreotti F., Watts G.F., et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J 2010, 31(23):2844-2853.
50. Tselmin S., Julius U., Muller G., Fischer S., Bornstein S.R. Cardiovascular events in patients with increased lipoprotein(a) - retrospective data analysis in an outpatient department of lipid disorders. Atheroscle Suppl 2009, 10(5):79-84.
51. Kim B.S., Jung H.S., Bang O.Y., Chung C.S., Lee K.H., Kim G.M. Elevated serum lipoprotein(a) as a potential predictor for combined intracranial and extracranial artery stenosis in patients with ischemic stroke. Atherosclerosis 2010, 212(2):682-688.
52. Parhofer K.G. Lipoprotein(a): medical treatment options for an elusive molecule. Curr Pharm Des 2011, 17(9):871-876.
53. Armstrong V.W., Schuff-Werner P., Eisenhauer T., Helmhold M., Stix M., Seidel D. Heparin extracorporeal LDL precipitation (HELP): an effective apheresis procedure for lowering Lp(a) levels. Chem Phys Lipids 1994, 67-68:315-321.
54. Banyai S., Streicher J., Strobl W., Gabriel H., Gottsauner-Wolf M., Rohac M., et al. Therapeutic efficiency of lipoprotein(a) reduction by low-density lipoprotein immunoapheresis. Metabolism 1998, 47(9):1058-1064.
55. Hovland A., Marcovina S., Hardersen R., Enebakk T., Mollnes T.E., Lappegard K.T. Three different LDL apheresis columns efficiently and equally reduce lipoprotein(a) concentrations in patients with familial hypercholesterolemia and small apolipoprotein(a) particles. Transfus Apher Sci 2012, 46(1):73-76.
56. Ibrahim M., Ussen B., Pottle A., Barbir M. Low-density lipoprotein apheresis is effective in reducing lipoprotein(a) levels and in improving symptoms in a patient with refractory angina secondary to accelerated coronary artery disease. J Clin Lipidol 2012, 6(2):192-194.
57. Stefanutti C., Vivenzio A., Di G.S., Mazzarella B., Ferraro P.M., Abbolito S. Treatment of symptomatic hyperLp(a)lipidemia with LDL-apheresis vs. usual care. Transfus Apher Sci 2010, 42(1):21-26.
58. Julius U, Fischer S, Schatz U, Passauer J, Bornstein SR. Why an apheresis center should offer more than one lipoprotein apheresis method. Ther Apher Dial, doi:10.1111/j.1744-9987.2012.01129.x.
59. Jaeger B.R., Richter Y., Nagel D., Heigl F., Vogt A., Roeseler E., et al. Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events. Nat Clin Pract Cardiovasc Med 2009, 6(3):229-239.
60. von Dryander M., Julius U., Fischer S., Passauer J., Mueller G., Bornstein S.R. Differences in the atherogenic risk of patients treated by lipoprotein apheresis according to their lipid pattern. Atheroscler Suppl 2013, 14(1):39-44.
61. Lin C.L., Tang Y.L., Lin S.M. Efficient bioconversion of compactin to pravastatin by the quinoline-degrading microorganism Pseudonocardia carboxydivorans isolated from petroleum-contaminated soil. Bioresour Technol 2011, 102(22):10187-10193.
62. Weng T.C., Yang Y.H., Lin S.J., Tai S.H. A systematic review and meta-analysis on the therapeutic equivalence of statins. J Clin Pharm Ther 2010, 35(2):139-151.
63. Mora S., Glynn R.J., Boekholdt S.M., Nordestgaard B.G., Kastelein J.J., Ridker P.M. On-treatment non-high-density lipoprotein cholesterol, apolipoprotein B, triglycerides, and lipid ratios in relation to residual vascular risk after treatment with potent statin therapy: JUPITER (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin). J Am Coll Cardiol 2012 April 24, 59(17):1521-1528.
64. Heintjes E.M., Penning-van Beest F.J., Plat A.W., Meerding W.J., Webb K., Sturkenboom M.C., et al. Cholesterol level goal attainment with statins: clinical management guideline recommendations versus management in actual clinical practice. Pharmacotherapy 2012, 32(7):631-641.
65. Brown W.V. Novel approaches to lipid lowering: what is on the horizon?. Am J Cardiol 2001, 87(5A):23-27.
66. Asano S., Ban H., Tsuboya N., Uno S., Kino K., Ioriya K., et al. A novel class of antihyperlipidemic agents with low density lipoprotein receptor up-regulation via the adaptor protein autosomal recessive hypercholesterolemia. J Med Chem 2010, 53(8):3284-3295.
67. Gotto A.M., Moon J.E. Recent clinical studies of the effects of lipid-modifying therapies. Am J Cardiol 2012, 110(1 Suppl.):15-26.
68. Raal F.J., Santos R.D. Homozygous familial hypercholesterolemia: current perspectives on diagnosis and treatment. Atherosclerosis 2012 Feb 16, [Epub ahead of print].
69. Cuchel M., Bloedon L.T., Szapary P.O., Kolansky D.M., Wolfe M.L., Sarkis A., Millar J.S., Ikewaki K., et al. Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. N Engl J Med 2007, 356(2):148-156.
70. Samaha Frederick F., McKenney James, Bloedon LeAnne T., Sasiela William J., Rader Daniel J. Impact of the MTP-inhibitor, AEGR-733, as monotherapy and in combination with ezetimibe on lipid subfractions as measured by NMR spectroscopy. Circulation 2008, 118(5):469.
71. Cariou B., Le May C., Costet P. Clinical aspects of PCSK9. Atherosclerosis 2011, 216(2):258-265.
72. Seidah N.G. PCSK9 as a therapeutic target of dyslipidemia. Expert Opin Ther Targets 2009, 13:19-28.
73. Duff C.J., Hooper N.M. PCSK9: an emerging target for treatment of hypercholesterolemia. Expert Opin Ther Targets 2011, 15(2):157-168.
74. Kastelein J.J., Wedel M.K., Baker B.F., Su J., Bradley J.D., Yu R.Z., et al. Potent reduction of apolipoprotein B and LDL cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B. Circulation 2006, 114:1729-1735.
75. Thompson G.R. LDL apheresis. Atherosclerosis 2003, 167:1-13.
76. Stefanutti C., Lanti A., Di Giacomo S., Mareri M., De Lorenzo F., Landolfo A., et al. Therapeutic apheresis in low weight patients: technical feasibility, tolerance, compliance, and risks. Transfus Apher Sci 2004, 31(1):3-10.
77. Stefanutti C. The 2009 2nd Italian consensus conference on LDL-apheresis. Nutr Metab Cardiovasc Dis 2010, 20(10):761-762.
78. Stefanutti C., Vivenzio A., Di Giacomo S., Mazzarella B., Bosco G., Berni A. Aorta and coronary angiographic follow-up of children with severe hypercholesterolemia treated with low-density lipoprotein apheresis. Transfusion 2009, 49(7):1461-1470.
79. Rossebø A.B., Pedersen T.R., Boman K., Brudi P., Chambers J.B., Egstrup K., et al. SEAS Investigators: intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 2008 Sep 25, 359(13):1343-1356.
80. Pazianas M. Calcific aortic stenosis. N Engl J Med 2009 Jan 1, 360(1):85-86.
81. Cawley P.J., Otto C.M. Prevention of calcific aortic valve stenosis fact or fiction?. Ann Med 2009, 14:1-9.
82. Klingel R., Göhlen B., Schwarting A., Himmelsbach F., Straube R. Differential indication of lipoprotein apheresis during pregnancy. Ther Apher Dial 2003, 7(3):359-364.
83. Cashin-Hemphill L., Noone M., Abbott J.F., Waksmonski C.A., Lees R.S. Low-density lipoprotein apheresis therapy during pregnancy. Am J Cardiol 2000 Nov 15, 86(10):1160. A10.
84. Teruel J.L., Lasunción M.A., Navarro J.F., Carrero P., Ortuño J. Pregnancy in a patient with homozygous familial hypercholesterolemia undergoing low-density lipoprotein apheresis by dextran sulfate adsorption. Metabolism 1995, 44(7):929-933.
85. Stefanutti C., Di Giacomo S., Vivenzio A., Bosco G., Colloridi V., Trizza S., et al. LDL-apheresis in the treatment of familial hypercholesterolemia in childhood. Atherosclerosis 1997, 134(1-2):412. 383-384.